title: Inhibitory effects of resveratrol on MCP-1, IL-6, and IL-8 production in human coronary artery smooth muscle cells.
abstract: Resveratrol, a representative polyphenol compound, is known to have antiatherogenic effects through its various actions including an anti-inflammatory action. The processes of initiation and progression of atherosclerosis are mediated by proinflammatory cytokines. The aim of this study was to determine whether resveratrol affects cytokine production in human coronary artery smooth muscle cells (HCASMCs). Each cytokine concentration in the culture medium of HCASMCs was measured by flow cytometry using the cytometric bead array system, and extracellular signal-regulated kinase (ERK) activity was evaluated by Western blotting. Basal levels of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, and IL-8 were significantly decreased in the presence of resveratrol at 1-50 μM in a concentration-dependent manner and were significantly decreased in the presence of U0126, an ERK inhibitor. Resveratrol significantly decreased both basal and interferon-γ (IFN-γ) (200 ng/ml)-stimulated levels of MCP-1, IL-6, and IL-8 and significantly attenuated both basal and IFN-γ-stimulated activity of ERK. TNF-α, IL-1β, IL-10, and IL-12p70 were detected only as trace levels in the culture medium with or without IFN-γ. Therefore, resveratrol is thought to inhibit production of MCP-1, IL-6, and IL-8 in HCASMCs through attenuating ERK activity. Inhibition of cytokine production in coronary artery smooth muscle cells may in part explain antiatherogenic action of resveratrol.
authors: Department of Environmental and Preventive Medicine, Hyogo College of Medicine, Mukogawa-cho 1-1, Nishinomiya, Hyogo, 663-8501, Japan. wakabaya@hyo-med.ac.jp
authors: Ichiro
authors: I
authors: Wakabayashi
authors: Yuji
authors: Y
authors: Takeda
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D002478:Cells, Cultured; D003331:Coronary Vessels / Q000166:cytology*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism; D048049:Extracellular Signal-Regulated MAP Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D032389:Myocytes, Smooth Muscle / Q000187:drug effects* / Q000378:metabolism; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D016207:Cytokines; D013267:Stilbenes; D048049:Extracellular Signal-Regulated MAP Kinases; D000077185:Resveratrol
references: Crit Rev Clin Lab Sci. 2002 Jun;39(3):225-83
references: 12120782
references: Eur Heart J. 2007 Jul;28(14):1683-93
references: 17561496
references: Am J Physiol Heart Circ Physiol. 2006 Oct;291(4):H1694-9
references: 16973825
references: Circ Res. 2000 Aug 4;87(3):179-83
references: 10926866
references: Atherosclerosis. 2010 Mar;209(1):58-65
references: 19733855
references: Int J Cardiol. 2009 Aug 21;136(3):263-9
references: 18656273
references: Mol Nutr Food Res. 2005 May;49(5):377-95
references: 15830334
references: Alcohol Alcohol. 2002 Sep-Oct;37(5):409-15
references: 12217928
references: Nitric Oxide. 2012 Feb 15;26(2):102-10
references: 22245452
references: Nat Med. 2011 Nov 07;17(11):1410-22
references: 22064431
references: J Vasc Res. 2007;44(1):75-84
references: 17191021
references: FEBS Lett. 1999 May 14;451(1):63-7
references: 10356984
references: Ann N Y Acad Sci. 2002 May;957:7-15
references: 12074957
references: Hypertens Res. 2009 Jun;32(6):466-71
references: 19373235
references: Toxicol In Vitro. 2009 Oct;23(7):1284-91
references: 19631264
references: Eur J Pharmacol. 2005 May 16;515(1-3):1-9
references: 15878161
references: J Nutr. 2005 Dec;135(12):2767-73
references: 16317118
references: Eur J Pharmacol. 2010 Mar 10;629(1-3):1-6
references: 19958762
references: J Am Coll Surg. 2005 Mar;200(3):428-39
references: 15737855
references: Vascul Pharmacol. 2009 Jan-Feb;50(1-2):34-9
references: 18824136